A carregar...
Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies
The approval of a multitargeted receptor tyrosine kinase inhibitor, sorafenib, with activity against vascular endothelial growth factor receptor-2 and -3, Raf-1 and B-Raf, platelet-derived growth factor receptor-α and -β, and other kinases, has ushered in the era of molecular targeted agents in adva...
Na minha lista:
| Publicado no: | Cancer J |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792519/ https://ncbi.nlm.nih.gov/pubmed/19672141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e3181af5e35 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|